2026.07.01
Reforgene named among China's Top 100 Innovative Pharmaceutical Companies 2026
Reforgene was recognized as one of China's Top 100 Innovative Pharmaceutical Companies for 2026.
Latest Updates
Reforgene named a Future Healthcare Top 100 company for the fourth consecutive year
Reforgene has been listed among the Future Healthcare Top 100 for four consecutive years.
Guangzhou Industry and Information Technology Bureau delegation visits Reforgene
A delegation from the Guangzhou Municipal Industry and Information Technology Bureau visited Reforgene to discuss the high-quality development of the gene editing industry.
TIF and the Angel Mama Foundation visit Reforgene to advance global access for thalassemia gene medicine
The Thalassaemia International Federation (TIF) and the Angel Mama Foundation visited Reforgene to jointly advance globalization and patient access for thalassemia gene medicines.
Guangzhou Municipal Government delegation visits Reforgene
A delegation led by the Deputy Secretary-General of the Guangzhou Municipal Government visited Reforgene to support the high-quality development of the gene editing industry.
Reforgene approved as a postdoctoral research workstation sub-station
Reforgene was approved to establish a postdoctoral research workstation sub-station, strengthening its talent base for gene editing medicine innovation.
Reforgene listed among China's 2025 biopharma frontrunners
Reforgene was named to the 2025 China Biopharmaceutical Frontrunner list.
Reforgene named a 2024 Top 50 most influential healthcare company
Reforgene was recognized as one of the most influential healthcare companies of 2024.
Reforgene named a 2025 Future Healthcare Top 100 company for the third consecutive year
Reforgene was listed among the 2025 Future Healthcare Top 100 for the third consecutive year.
View all news (48 items)
2025.05.08